Novo Nordisk Cuts Wegovy Prices in Competitive Indian Market

Danish pharmaceutical company Novo Nordisk has announced a price reduction of its weight-loss drug, Wegovy, by up to 37% in India. This strategic move aims to enhance its market position in a rapidly growing sector for obesity treatments, which analysts project could reach a value of $150 billion annually by the end of the decade. The new monthly price for Wegovy's highest dose of 2.4 mg is now set at 16,400 rupees ($186.59), down from 24,389.06 rupees, while the lowest dose of 0.25 mg will cost 10,850 rupees, reduced from 16,260.94 rupees. This price adjustment follows a revision in the national sales tax structure in September, which contributed to the drug's decreased cost.

ReutersAvidity Biosciences Slides On Wider Losses But Keeps Big Plans

India has emerged as a critical battleground for Novo Nordisk and its U.S. rival Eli Lilly, which launched its weight-loss drug, Mounjaro, in March. Mounjaro's sales have reportedly doubled within months of its introduction, making it the top-selling drug by value in India as of October. Vikrant Shrotriya, managing director of Novo Nordisk India, emphasized the company's commitment to listening to the needs of patients and healthcare providers, stating, "We have made sure to listen to our patient and doctor communities and take active measures for the benefit of people at large."

Reuters

Analysts suggest that the price cut is a strategic response to the competitive pressure from Mounjaro and the impending entry of generic versions of Wegovy, which are expected to flood the market after the drug's patent expires in March 2026. Systematix Institutional Equities analyst Vishal Manchanda noted that the price reduction could enhance Novo's competitiveness in light of Mounjaro's success. Both companies are also pursuing partnerships with local firms to expand their distribution networks in India, with Eli Lilly collaborating with Cipla and Novo Nordisk with Emcure Pharma.

Reuters

While the price cut is seen as a necessary step for Novo Nordisk to maintain its market share, it also raises concerns about the long-term sustainability of drug pricing in the obesity treatment sector. Critics argue that aggressive pricing strategies may lead to a race to the bottom, potentially compromising the quality of care. The competitive dynamics between Novo Nordisk and Eli Lilly could result in price wars, affecting profit margins and patient access to these essential medications.

Eli Lilly Removes CVS from Employee Drug Plan Following Weight-Loss Drug Snub

• “We have made sure to listen to our patient and doctor communities and take active measures for the benefit of people at large,” — Vikrant Shrotriya, Managing Director, Novo Nordisk India

Reuters

• “This could also be because generics are also entering the market in 2026, so a lower price will help Novo compete better,” — Vishal Manchanda, Analyst, Systematix Institutional Equities

Reuters

Novo Nordisk's decision to reduce Wegovy's price reflects the intense competition in the obesity treatment market in India. As the landscape evolves with the introduction of generics and rival products, the implications for pricing strategies and patient access will be significant. The ongoing rivalry between Novo Nordisk and Eli Lilly will likely shape the future of obesity treatments in India and beyond.

Reuters